Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology
Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology
复制标题
DOI：
10.1111/jth.15341
复制
发表时间：
2021-05-20
影响因子：
10.4
通讯作者：
Bakchoul, Tamam
中科院分区：
文献类型：
--
作者：
Nazy, Ishac;Sachs, Ulrich J.;Bakchoul, Tamam
疫苗接种正在全球范围内进行，以对抗当前的COVID-19大流行。新开发的疫苗非常有效，副作用最小。最近，阿斯利康ChadOx 1 nCov-19疫苗引起了公众对罕见但严重的血栓形成事件（现在称为疫苗诱导的免疫性血栓性血小板减少症（VITT））的担忧。这些血栓形成事件在临床和病理学上与肝素诱导的血小板减少症相似。在这份手稿中，ISTH SSC血小板免疫学小组委员会概述了如何识别，诊断和管理VITT患者的指南。
Vaccine administration is under way worldwide to combat the current COVID-19 pandemic. The newly developed vaccines are highly effective with minimal adverse effects. Recently, the AstraZeneca ChadOx1 nCov-19 vaccine has raised public alarm with concerns regarding the rare, but serious, development of thrombotic events, now known as vaccine-induced immune thrombotic thrombocytopenia (VITT). These thrombotic events appear similar to heparin-induced thrombocytopenia, both clinically and pathologically. In this manuscript, the ISTH SSC Subcommittee on Platelet Immunology outlines guidelines on how to recognize, diagnose and manage patients with VITT.